A PHASE 1, OPEN-LABEL, DOSE ESCALATION AND DOSE EXPANSION STUDY OF CLN-049 FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) PATIENTS WITH MEASURABLE RESIDUAL DISEASE (MRD)

Nicht-Interventionelle Studie (NIS) zum klinischen Einsatz von Octagam 5%, Octagam 10% oder panzyga

Prospektive Datenerfassung zu Diagnostik, Behandlung und Krankheitsverlauf der ALL des Erwachsenen und verwandter Erkrankungen in Verbindung mit einer prospektiven Biomaterialsammlung

A multicentre, randomized trial in adults with de novo Philadelphia-Chromosome positive acute lymphoblastic leukemia to assess the efficacy of ponatinib versus imatinib in combination with low-intensity chemotherapy, to compare subsequent allogeneic stem cell transplantation (SCT) versus TKI in combination with blinatumomab and chemotherapy in optimal responders and to evaluate blinatumomab before SCT in suboptimal responders (GMALL-EVOLVE)

AML-Register und Biomaterialdatenbank der Studienallianz Leukämie (SAL) und der AML Cooperative Group (AML-CG)

Michigan Acute Graft-versus-Host Disease International Consortium (MAGIC): A Database and Biorepository to prospectively collect HCT data, complications and outcomes pertinent to graft-versus-host disease from allogeneic HCT patients for future analysis
To prospectively collect and store blood for future analysis from allogeneic HCT patients

EvAluation of the efficacy of MaaT013 as salvage theRapy in acute GVHD patiEntS with gastrointestinal involvement, refractory to ruxolitinib; a multi-center open-label phase III trial.

National acute promyelocytic leukemia (APL) observational study NAPOLEON‐Register der Deutschen AML Intergroup

Nicht – interventionelle Unbedenklichkeitsstudie zur Verträglichkeit und Sicherheit von Octagam 5 % und Octagam 10 %; Therapie im Rahmen der Zulassung